Ebos Group: Solid as usual, now planning for life without CW

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

24 August 2023, 7:00 AM

Sectors Covered:

Healthcare, Life Sciences

• Ebos Group (ASX:EBO) reported another year of consistent earnings growth (up 14.1%) which benefitted from acquisitions in the medical technology and consumables category.
• Although no specific guidance was provided, profitable growth is expected to continue (MorgansF EPS growth of 11.7%). An update will be provided at the AGM in October.
• We have increased our NPAT by ~8% over the forecast period which increases our valuation and target price to (login to view). Add maintained.

Find out more

You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.

If you would like more information, please contact your adviser or nearest Morgans office.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.